Phadwal Kanchan, Vrahnas Christina, Ganley Ian G, MacRae Vicky E
Functional Genetics and Development Division, The Roslin Institute and The Royal (Dick) School of Veterinary Studies (R(D)SVS), University of Edinburgh, Midlothian, United Kingdom.
Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, University of Dundee, Dundee, United Kingdom.
Front Cell Dev Biol. 2021 Mar 16;9:611922. doi: 10.3389/fcell.2021.611922. eCollection 2021.
Mitochondria are crucial bioenergetics powerhouses and biosynthetic hubs within cells, which can generate and sequester toxic reactive oxygen species (ROS) in response to oxidative stress. Oxidative stress-stimulated ROS production results in ATP depletion and the opening of mitochondrial permeability transition pores, leading to mitochondria dysfunction and cellular apoptosis. Mitochondrial loss of function is also a key driver in the acquisition of a senescence-associated secretory phenotype that drives senescent cells into a pro-inflammatory state. Maintaining mitochondrial homeostasis is crucial for retaining the contractile phenotype of the vascular smooth muscle cells (VSMCs), the most prominent cells of the vasculature. Loss of this contractile phenotype is associated with the loss of mitochondrial function and a metabolic shift to glycolysis. Emerging evidence suggests that mitochondrial dysfunction may play a direct role in vascular calcification and the underlying pathologies including (1) impairment of mitochondrial function by mineral dysregulation i.e., calcium and phosphate overload in patients with end-stage renal disease and (2) presence of increased ROS in patients with calcific aortic valve disease, atherosclerosis, type-II diabetes and chronic kidney disease. In this review, we discuss the cause and consequence of mitochondrial dysfunction in vascular calcification and underlying pathologies; the role of autophagy and mitophagy pathways in preventing mitochondrial dysfunction during vascular calcification and finally we discuss mitochondrial ROS, DRP1, and HIF-1 as potential novel markers and therapeutic targets for maintaining mitochondrial homeostasis in vascular calcification.
线粒体是细胞内至关重要的生物能量发电站和生物合成中心,能够响应氧化应激产生并隔离有毒的活性氧(ROS)。氧化应激刺激的ROS产生会导致ATP耗竭以及线粒体通透性转换孔的开放,从而导致线粒体功能障碍和细胞凋亡。线粒体功能丧失也是获得衰老相关分泌表型的关键驱动因素,该表型会使衰老细胞进入促炎状态。维持线粒体稳态对于保持血管平滑肌细胞(VSMC)的收缩表型至关重要,VSMC是脉管系统中最突出的细胞。这种收缩表型的丧失与线粒体功能丧失以及代谢向糖酵解的转变有关。新出现的证据表明,线粒体功能障碍可能在血管钙化及相关潜在病理过程中起直接作用,包括(1)矿物质失调导致的线粒体功能受损,即终末期肾病患者的钙和磷过载,以及(2)钙化性主动脉瓣疾病、动脉粥样硬化、II型糖尿病和慢性肾病患者中ROS增加。在本综述中,我们讨论了血管钙化及相关潜在病理过程中线粒体功能障碍的原因和后果;自噬和线粒体自噬途径在预防血管钙化过程中线粒体功能障碍方面的作用;最后,我们讨论了线粒体ROS、动力相关蛋白1(DRP1)和缺氧诱导因子1(HIF-1)作为维持血管钙化中线粒体稳态的潜在新标志物和治疗靶点。